Background: Prevalence of recurrent calcium-oxalate (CaOx) urolithiasis (UL) is up to fivefold higher in Crohn's disease than in the general population. Treatment options are scarce and the risk of recurrent UL or progressive renal CaOx deposition, (oxalosis) based early end-stage renal failure (ESRF), subsequent systemic oxalosis, and recurrence in the kidney graft is pronounced. We aimed to find proof that secondary hyperoxaluria is the main risk factor for the devastating course and correlates with intestinal oxalate absorption.
Methods: 24-h urines were collected and analyzed for urinary oxalate (Uox) in 27 pediatric (6-18 years) and 19 adult patients (20-62 years). In the 21 patients (8 adults and 13 children) with hyperoxaluria a [(13)C(2)]oxalate absorption test was performed under standardized dietary conditions.
Results: Mean Uox was significantly higher in patients with UL or oxalosis (0.92 ± 0.57) compared with those without (0.53 ± 0.13 mmol/1.73 m(2)/24 h, p<0.05, normal < 0.5). Hyperoxaluria then significantly correlated with intestinal oxalate absorption (p< 0.05).
Conclusion: As UL/oxalosis has major implications for the general health in patients with Crohn's disease (ESRF and systemic oxalosis), new medication, e.g. to reduce intestinal oxalate absorption, is definitely needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00467-012-2126-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8).
Pediatr Nephrol
January 2025
Novo Nordisk A/S, Lexington, MA, USA.
Background: Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder with dysregulated glyoxylate metabolism in the liver. Oxalate over-production leads to renal stones, progressive kidney damage and renal failure, with potentially life-threatening systemic oxalosis. Nedosiran is a synthetic RNA interference therapy, designed to reduce hepatic lactate dehydrogenase (LDH) to decrease oxalate burden in PH.
View Article and Find Full Text PDFSecondary hyperoxaluria: Cause and consequence of chronic kidney disease.
Nefrologia (Engl Ed)
January 2025
Servicio de Nefrología, Hospital Universitario de la Princesa, Madrid, Spain. Electronic address:
Secondary hyperoxaluria is a metabolic disorder characterized by an increase in urinary oxalate excretion. The etiology may arise from an increase in the intake of oxalate or its precursors, decreased elimination at the digestive level, or heightened renal excretion. Recently, the role of the SLC26A6 transporter in the etiopathogenesis of this disease has been identified.
View Article and Find Full Text PDFUnveiling primary Hyperoxaluria type 1: a fortuitous discovery through bone marrow biopsy.
Oxf Med Case Reports
October 2024
Pathology Department, Ibn Sina Hospital, Rabat, Morocco.
Article Synopsis
- A 46-year-old woman with chronic kidney issues and kidney stones was diagnosed with primary hyperoxaluria type 1 (PH1) through a bone marrow biopsy.
- Genetic testing revealed a specific mutation (p.Ile244Thr) in the AGXT gene, which is linked to the disorder.
- The paper emphasizes the need for early diagnosis of kidney stone issues, especially in families with a history of the condition, to avoid severe kidney damage and systemic complications.
Efficient and safe in vivo treatment of primary hyperoxaluria type 1 via LNP-CRISPR-Cas9-mediated glycolate oxidase disruption.
Mol Ther
January 2025
Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai 200241, China; Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China; YolTech Therapeutics, Shanghai 201109, China. Electronic address:
Article Synopsis
- Primary hyperoxaluria type 1 (PH1) is a severe genetic disorder caused by AGXT gene mutations, leading to dangerous oxalate buildup, kidney damage, and renal failure.
- Current therapies like siRNA and CRISPR-Cas9 have limitations, including the need for repeated treatments and safety issues.
- The study introduces lipid nanoparticles (LNPs) for CRISPR-Cas9 delivery, effectively targeting the Hao1 gene, which decreased oxalate levels in mice with PH1, showing efficacy and long-lasting effects without significant side effects, indicating a safer treatment option for PH1.
Late-onset retinal oxalosis in primary hyperoxaluria type 2.
Am J Ophthalmol Case Rep
December 2024
Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, USA.
Purpose: To report a previously undescribed case of late-onset vision loss due to retinal oxalosis in a patient with primary hyperoxaluria type 2 (PH2).
Observations: An 82-year-old female with a history of biopsy-proven oxalate nephropathy developed vision loss 8 months after end stage kidney disease. She developed progressive retinal ischemia secondary to crystal deposition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!